| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4433 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-02 |
| filingDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_273451692658753af83ff0b618ddc598
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_449a24784f1e9c54a4d8590f9ca07b3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a45fb277ec2701e14ee8d4cc0b637db2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3318c52343f15878840f98544f5ae1b |
| publicationDate |
2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020010429-A2 |
| titleOfInvention |
use of kor agonist in combination with mor agonist in drug preparation for pain treatment |
| abstract |
the use of a kor agonist in combination with a mor agonist in the preparation of a drug for the treatment of pain is described. the kor agonist is selected from a compound as shown in the general formula (i), and the mor agonist is selected from a compound as shown in the general formula (ii), where the definitions of each substituent in the general formula (i) and (ii) are the same as defined in the description. |
| priorityDate |
2017-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |